Alio Participates in Controversies in Dialysis Access (CiDA) Conference
BROOMFIELD, Colo., December 12, 2021 / —
Dave Kuraguntla, CEO and Founder of Alio™, a medical technology company reinventing the management and monitoring of chronic disease, presented today at the New Technologies Symposium at the Controversies in Dialysis Access (CiDA) Conference.
Data was presented on how Alio is closing the gap on remote patient monitoring, with product development improvements and increased insights from Alio algorithms. Clinical data illustrates the ability of the wearable Alio SmartPatch to non-invasively measure blood pressure (BP), Hematocrit (Hct), and serum potassium (K+) in hemodialysis patients with an arteriovenous (AV) fistula. Clinical data further demonstrates the efficacy of the end-to-end Alio SmartPatch remote monitoring data pathway.
CiDA is an annual meeting of world-renowned leaders in hemodialysis, gathering to review the latest data and technologies in dialysis. CiDA is an international symposium founded as a leading educational forum for surgeons, radiologists, nephrologists, and medical staff who care for dialysis access patients.
Overall, the presentation was well-received and generated positive comments and questions regarding the current clinical and development status of Alio™.
About Alio
Alio Medical™, a division of Alio, Inc. (Broomfield, CO), is a medical technology company developing SmartPatch™ technology and using artificial intelligence (AI) to monitor multiple chronic indications, including end stage kidney disease (ESKD) patients undergoing hemodialysis. Alio is dedicated to the development of remote monitoring that provides actionable clinical data for a variety of conditions to better target interventions for improved outcomes and reduced hospitalizations.
